MediPharm Forms a New Supply Arrangement for Premium Cannabis-Infused Products

Australia's leadership in the APAC medical cannabis market

“We are committed to delivering the highest quality products to our customers throughout Atlantic Canada and doing so in partnership with MediPharm Labs is a virtual guarantee of success,” said Dave Thomson, President of Argentia Gold. “As our white-label supply partner, MediPharm Labs is able to address exactly what we need: reliable, responsive production that meets Good Manufacturing Practice (GMP) standards backed by some of the cannabis industry’s most knowledgeable scientists, pharmaceutical professionals and extraction specialists. Argentia Gold’s destination is market leadership and this agreement is an important milestone in our journey.”

  • MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) Argentina Gold Corporation, a Canadian vertically integrated licensed producer, announced a new supply arrangement to bring premium cannabis-infused products to Atlantic Canada.
  • Initial 2 year agreement.
  • MediPharm Labs will provide Argentia Gold-branded formulated tincture bottles of CBD cannabis resin and Argentia Gold will provide distribution, sales, and service to leading retailers in Newfoundland and Labrador, Prince Edward Island, Nova Scotia and New Brunswick.

About Argentia

Argentia Gold is one of Newfoundland and Labrador’s vertically integrated licensed producers fully authorized to cultivate and process premium cannabis, manufacture and package CBD and THC-infused products such as beverages, medical creams, and beauty items. Its facility, a former U.S. naval base turned industrial park on the deep-water Port of Argentia, encompasses approximately 80,000 square feet on 10 acres of land.  With a focus on providing Canadians a top-level experience with cannabis-infused products, Argentia Gold leverages its technology, management team and key government collaboration to deliver a direct-to-retail experience rivaling other companies in the market.

About MediPharm Labs

See Price movement, Financials and News

Founded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical-quality cannabis oil and concentrates and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities with five primary extraction lines for delivery of pure, trusted and precision-dosed cannabis products for its customers. Through its wholesale and white label platforms, MediPharm Labs formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. As a global leader, MediPharm Labs has completed commercial exports to Australia and is nearing commercialization of its Australian extraction facility. MediPharm Labs Australia was established in 2017.

Source

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s